Randomized Phase III Trial of Local Consolidation Therapy (LCT) After Nivolumab and Ipilimumab for Immunotherapy-Naive Patients With Metastatic Non-Small Cell Lung Cancer (LONESTAR) -Strategic Alliance: BMS
Phase of Trial: Phase III
Latest Information Update: 16 Nov 2018
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms LONESTAR
- 02 Nov 2018 Planned End Date changed from 1 Dec 2023 to 1 Dec 2022.
- 07 Feb 2018 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 08 Jan 2018 New trial record